Table 7. Intermediate health outcomes (1)

| Study, year | Study group | Followup | BSAmean(SD) | PGA\* n/N | Patient’s Assessment of Global Improvement mean(SD) | Symptom improvement |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  |  |  |  |  | Pruritus | Pain | Other |
| CT5, 2012 | Etanercept | 2w4w8w12w18w24w | -2.64(6.69)†-7.36(10.89)†-12.67(13.17)†-15.43(14.90)†-16.57(14.70)†-17.52(14.91)† | 0/214/216/219/217/2111/21 | -0.90(1.58)‡-1.86(1.28)‡-2.29(1.79)‡-2.67(1.56)‡-2.57(1.99)‡-1.81(2.20)‡ | -0.67(1.59)§-1.52(1.33)§-1.86(2.06)§-2.10(2.07)§-1.81(2.06)§-1.19(2.23)§ | 0.00(0.71)||0.29(1.19)||0.19(0.81)||0.00(0.63)||-0.05(0.67)||0.29(1.06)|| |  |
|  | Acitretin | 2w4w8w12w18w24w | -0.36(5.54)†-0.75(7.66)†-5.14(16.96)†-5.08(11.89)†-9.25(16.72)†-10.30(18.86)† | 1/182/181/181/183/188/18 | -0.72(1.02)‡-0.83(1.04)‡-1.67(1.71)‡-1.61(1.72)‡-1.83(1.76)‡-1.72(1.93)‡ | -0.39(1.29)§-0.39(2.03)§-1.28(1.71)§-1.22(1.73)§-1.17(1.62)§-1.06(1.89)§ | -0.44(1.10)||-0.72(1.81)||-0.56(1.72)||-0.44(2.36)||-0.44(1.85)||-0.61(2.03)|| |  |
| Gelfand, 2012 | MTX | --- | 3.0(1.0 to 6.0)¶ | 1.7(1.3 to 2.0)¶ | --- | --- | --- | --- |
|  | Adalimumab | --- | 2.0(0.7 to 5.0)¶ | 1.3(1.0 to 1.7)¶ | --- | --- | --- | --- |
|  | Etanercept | --- | 2.0(0.5 to 4.5)¶ | 1.7(1.0 to 2.0)¶ | --- | --- | --- | --- |
|  | Ustekinumab | --- | 3.0(0.6 to 9.1)¶ | 1.7(1.0 to 2.1)¶ | --- | --- | --- | --- |
|  | NB-UVB | --- | 3.3(1.0 to 6.5)¶ | 1.7(1.0 to 2.0)¶ | --- | --- | --- | --- |
| Barker, 2011 | Infliximab | 16w26w\*\* | ------ | 496/653477/653 | ------ | ------ | ------ | ------ |
|  | MTX | 16w26w\*\* | ------ | 82/21560/215 | ------ | ------ | ------ | ------ |
|  | Infliximab transitioned to MTX | 18w22w26w | --------- | 0/91/92/9 | --------- | --------- | --------- | --------- |
|  | MTX transitioned to infliximab | 18w22w26w | --------- | 19/6345/6347/63 | --------- | --------- | --------- | --------- |
| Inzinger, 2011 | Adalimumab | --- | --- | --- | --- | --- | --- | --- |
|  | Alefacept | --- | --- | --- | --- | --- | --- | --- |
|  | Etanercept | --- | --- | --- | --- | --- | --- | --- |
|  | Infliximab | --- | --- | --- | --- | --- | --- | --- |
|  | Ustekinumab | --- | --- | --- | --- | --- | --- | --- |
|  | PUVA | --- | --- | --- | --- | --- | --- | --- |
| Strober, 2011 | MTX transitioned to adalimumab | 0w2w4w8w16w | --------------- | 1/410/4113/4122/4125/4161% (95%CI 45 to 76)†† | --------------- | -------------2.9(3.9)‡‡ | -------------14.7(24.4)§§ | ------------ |
|  | NB-UVB transitioned to adalimumab | 0w2w4w8w16w | --------------- | 0/293/296/2913/2914/2948% (95%CI 29 to 67)†† | --------------- | -------------3.0(2.96)‡‡ | -------------21.4(30.0)§§ | ------------ |
| Garavaglia, 2010 | CyA transitioned to etanercept | --- | --- | --- | --- | --- | --- | --- |
| Caproni, 2009 | Etanercept | --- | --- | --- | --- | --- | --- | --- |
|  | Acitretin | --- | --- | --- | --- | --- | --- | --- |
| Mazzotta, 2009 | Nonbiologics or phototherapy transitioned to etanercept|||| | --- | --- | --- | --- | --- | --- | --- |
| Gisondi, 2008a | Etanercept | 24w | -80.0%¶¶ | --- | --- | --- | --- | --- |
|  | Acitretin | 24w | -45.8%¶¶ | --- | --- | --- | --- | --- |
| Gisondi, 2008b | Etanercept | --- | --- | --- | --- | --- | --- | --- |
|  | Infliximab | --- | --- | --- | --- | --- | --- | --- |
|  | MTX | --- | --- | --- | --- | --- | --- | --- |
| Saurat, 2008 | Adalimumab | 4w8w12w16w | ------------ | 17/10852/10872/10879/108 | ----------1.6(NR)§ | ----------5.0(NR) | ----------24.2(NR) | ------------ |
|  | MTX | 4w8w12w16w | ------------ | 4/11010/11024/11033/110 | ----------1.2(NR)§ | ----------3.5(NR) | ----------11.1(NR) | ------------ |
|  | MTX transitioned to adalimumab | --- | --- | --- | --- | --- | --- | --- |
| Magliocco, 2007 | CyA transitioned to alefacept | 13w25w37w48w | ------------ | ---4.75(NR)\*\*\*4.33(NR)\*\*\*4.33(NR)\*\*\* | ------------ | ------------ | ------------ | ------------ |
| Costanzo, 2005 | Nonbiologics transitioned to etanercept††† | --- | --- | --- | --- | --- | --- | --- |

Abbreviations: BSA=body surface area; CI=confidence interval; CyA=cyclosporine; MTX=methotrexate; n/N=number of patients per total population; NB-UVB=narrowband ultraviolet B; NR=not reported; PASI=Psoriasis Area and Severity Index; PGA=Physician’s Global Assessment; PUVA=psoralen plus ultraviolet A; SD=standard deviation; VAS=visual analog scale; w=week(s); ---=not reported

\* Number of patients achieving a PGA score of “clear” or “minimal”, unless otherwise noted

† Mean(SD) change from baseline

‡ Mean(SD) change from baseline in SGA of psoriasis

§ Mean(SD) change from baseline in SGA of itching

|| Mean(SD) change from baseline is SGA of joint pain

¶ Median (IQR)

\*\* Includes patients who switched treatments at week 16 as nonresponders

†† 95%CI reported as percentage of respective population

‡‡ Mean(SD) change from baseline in Psoriasis-related Pruritus Assessment

§§ Mean(SD) change from baseline in VAS for pain involving psoriatic plaques and/or psoriatic arthritis

|||| CyA, corticosteroids, fumaric acid esters, MTX, retinoids, PUVA

¶¶ Mean percentage change from baseline

\*\*\* Mean(SD) PGA

††† CyA, corticosteroids, MTX, retinoids